medigraphic.com
ISSN 1995-9494 (Electronic)
Revista del Hospital Clínico Quirúrgico "Arnaldo Milián Castro"

2022, Number 4

<< Back Next >>

Acta Med Cent 2022; 16 (4)

Characterization of patients with adenoid syndrome

Mederos ME, Reyes HDL, Estupiñán MOR, Cruz VBR

Language: Spanish
References: 20
Page: 665-678
PDF size: 561.84 Kb.


ABSTRACT

Introduction: enlarged lymph nodes produce a group of symptoms and signs that constitute the adenopathy syndrome. Lymph node disease is called adenopathy.
Objective: to characterize patients who were admitted with adenoid syndrome to the Internal Medicine Service in the period from 2016 to 2018.
Methods: a descriptive cross-sectional study was performed. The population consisted of patients admitted with a diagnosis of adenoid syndrome who underwent lymph node biopsy with a conclusive clinical and pathological diagnosis, with a total of 103 patients.
Results: malignant adenopathies predominated in 74.8%, the average age of the patients was 57.48±17.25 years and male sex predominated (60.2%), lymph node metastases were the most frequent (33%), lung cancer, with nine patients, headed the causes of lymph node metastases and localized adenopathies predominated with 68% (36% were of cervical location). In patients with malignant lymphadenopathies, age over 50 years, male sex, white skin color, supraclavicular location, presence of accompanying symptoms such as weight loss and sweating and signs such as cutaneomucosal pallor and splenomegaly predominated.
Conclusions: malignant adenopathies, cervical location, patients with average age close to elderly, male and white were predominant. Metastases were more frequent in lung cancer. Weight loss, sweating, pallor and splenomegaly were the most frequently found symptoms and signs.


REFERENCES

  1. Nasr MR, Perry AM, Skrabek P. Histologic Examination and Ancillary Studies in Lymph Node Pathology. En: Lymph Node Pathology for Clinicians [Internet]. Cham: Springer Nature Switzerland AG; 2019 [citado 20/11/2021]. Disponible en: https://link.springer.com/chapter/10.1007/978-3-030-11515-9_21. . https://doi.org/10.1007/978-3-030-11515-9_2

  2. Nasr MR, Perry AM, Skrabek P. Basic Concepts in Lymph Node Pathology. En: Lymph Node Pathology for Clinicians [Internet]. Cham: Springer Nature Switzerland AG; 2019 [citado 20/11/2021]. Disponible en: https://link.springer.com/chapter/10.1007/978-3-030-11515-9_12. . https://doi.org/10.1007/978-3-030-11515-9_1

  3. López GA, Soca E. Linfomas y otrasenfermedades ganglionares. En: Farreras R. Medicina Interna. 19 ed. México: Mc-Graw Hill; 2020. p. 1671-1672.

  4. Bravo Moncayo HA, Vargas-Uricoechea H. Evaluación del paciente con linfadenopatías y esplenomegalia. En: Vargas-Uricoechea H, editor. Texto de Medicina Interna. 2a ed. Bogotá: Asociación Colombiana de Endocrinología, Diabetes y Metabolismo; 2021.

  5. Vargas Viveros JP, Hurtado Monroy R. Adenomegalia. Rev Fac Med (Méx) [Internet]. 2011 [citado 02/01/2022];54(4):10-23. Disponible en: https://www.scielo.org.mx/pdf/facmed/v54n4/v54n4a3.pdf5.

  6. Pastor IJ. Adenopatías, esplenomegalia. En: Laso JF. Diagnóstico diferencial en Medicina Interna. 3a ed. España: Elsevier; 2013.

  7. Armitage JO. Aproximación al paciente con adenopatías y esplenomegalia. En: Goldman-Cecil. Tratado de Medicina Interna. 25 ed. España: Elsevier; 2017.

  8. León P. Adenopatías. Semiología [Internet]. Santiago de Chile: Universidad de Chile; 2021 [citado 20/11/2021]. Disponible en: http://semiologia.med.uchile.cl/general/adenopatias/8.

  9. Moya EM, Pérez-Corral A, Pascual C, Casanova M, López-Quiñones A, Serrano M, et al. Adenopatías. En: Grupo Científico DTM. Green Book. Diagnóstico y Tratamiento Médico. 7a ed. España: Marbán; 2019.

  10. Ministerio de Salud Pública. Dirección de Registros Médicos y Estadísticas de Salud. Anuario Estadístico de Salud 2020 [Internet]. La Habana: MINSAP; 2021 [citado 12/12/2021]. Disponible en: https://files.sld.cu/bvscuba/files/2021/08/Anuario-Estadistico-Espa%c3%b1ol-2020-Definitivo.pdf10.

  11. Özkan EA, Göret CC, Özdemir ZT, Yanik S, Göret NE, Dogan M, et al. Evaluation of peripheral lymphadenopathy with excisional biopsy: six-year experience. Int J Clin Exp Pathol [Internet]. 2015 [citado 12/12/2021];8(11):15234-15239. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4713658/11.

  12. Olu-Eddo AN, Ohanaka CE. Peripheral lymphadenopathy in Nigerian adults. J Pak Med Assoc [Internet]. 2006 [citado 20/12/2021];56(9):405-408. Disponible en: https://pubmed.ncbi.nlm.nih.gov/17091753/12.

  13. Bosch X, Coloma E, Donate C, Colomo L, Doti P, Jordán A, et al. Evaluation of unexplained peripheral lymphadenopathy and suspected malignancy using a distinct quick diagnostic delivery model: prospective study of 372 patients. Medicine (Baltimore) [Internet]. 2014 [citado 20/12/2021];93(16):e95. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4616296/13. . https://doi.org/10.1097/md.0000000000000095

  14. Medscape [Internet]. New York: Medscape; c1994-2022 [actualizado 01/10/2021; citado 02/01/2022]. Pruritus and Systemic Disease; [aprox. 2 pantallas]. Disponible en: https://emedicine.medscape.com/article/1098029-overview14.

  15. Quintero Sierra Y, Teruel Herrero A, Hernández Padrón C, Concepción Fernández Y, Romero González A, Macia Pérez I. Caracterización del linfoma de Hodgkin en los pacientes adultos. Rev Cubana Hematol Inmunol Hemoter [Internet]. 2019 [citado 15/01/2022];35(3):e1027. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0864-0289201900030000615.

  16. Pérez-Zúñiga JM, Aguilar-Andrade C, Álvarez-Vera JL, Augusto-Pacheco M, Báez-Islas PE, Bates-Martín RA, et al. Linfoma de Hodgkin. Rev Hematol Mex [Internet]. 2019 [citado 15/01/2022];20(2):124-130. Disponible en: https://www.medigraphic.com/cgi-bin/new/resumen.cgi?IDARTICULO=8772016.

  17. Garcés Ortega JP, González Bracho JR, Ortiz Benavides RE, Quijije Castro JJ, Pacuruco Cajas JI, Vázquez Maita EG, et al. Linfoma de Hodgkin y no Hodgkin: desde una perspectiva molecular, diagnóstica y terapéutica. Arch Venez Farmacol Ter [Internet]. 2021 [citado 15/01/2022];40(3):310-321. Disponible en: https://www.redalyc.org/journal/559/55969712014/html/17. . https://doi.org/10.5281/zenodo.5041145

  18. Instituto Nacional del Cáncer [Internet]. Bethesda (MD): NIH (US); c1999-2022 [actualizado 25/06/2019; citado 15/01/2022]. Biopsia de ganglio centinela; [aprox. 9 pantallas]. Disponible en: https://www.cancer.gov/espanol/cancer/diagnostico-estadificacion/estadificacion/hoja-informativa-ganglio-centinela18.

  19. Nazario Dolz AM, Álvarez Matos D, Castillo Toledo L, Miyares Peña MV, Garbey Nazario A. Algunas especificidades en torno al cáncer de pulmón. Rev Cub Med Mil [Internet]. 2021 [citado 15/01/2022];50(1):e0210725. Disponible en: http://www.revmedmilitar.sld.cu/index.php/mil/article/view/725/66419.

  20. Uriburu JL, Rostagno R, Maciel A, Noblía C, Rafailovici L, Coló F, et al. Consenso Intersociedades 2018. Ganglio centinela positivo en estadios iniciales de cáncer de mama. Rev Arg Mastol [Internet]. 2018 [citado 15/01/2022];36(136):12-56. Disponible en: https://www.revistasamas.org.ar/revistas/2018_v37_n136/04.pdf20.




2020     |     www.medigraphic.com